Compare GE Vernova Inc (GEV) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs Novo Nordisk A/S — how do they compare? GE Vernova Inc trades at $1,004.73 (market cap $266.16B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: GE Vernova Inc is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 36 Days and Novo Nordisk A/S for 116 Days on average.
| GEV | NVO | |
|---|---|---|
Market Cap | $266.16B | $165.31B |
Volume | 2,324,165 | 11,432,838 |
Sector | Industrials | Health |
52-Week High | $1.17K | $63.98 |
52-Week Low | $547.96 | $35.29 |
Typical Hold Time | 36 Days | 116 Days |
Enterprise Value | $255.83B | $179.56B |
Dividend Yield | 0.2% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $999.35, up 0.23% with strong bullish technical signals and positive analyst sentiment. The stock shows impressive fundamentals with 91.48% ROE and 23.04% net income margin, though valuation multiples appear elevated with P/E of 28.65 and EV/EBITDA of 85.22. Recent developments include securing the first US construction permit for its BWRX-300 SMR and benefiting from AI-driven power demand growth.
Outlook remains positive with 75.86% analyst buy ratings and $1,270 consensus price target representing 27% upside. Key risks include execution challenges in wind power segment and stretched valuations. The company's $176 billion backlog and AI infrastructure positioning support long-term growth potential despite near-term valuation concerns.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
